Koltan names Frank Karbe to board
This article was originally published in Scrip
New Haven, Connecticut-based Koltan Pharmaceuticals has named Frank Karbe, former chief financial officer of Exelixis, to its board of directors. Mr Karbe has more than two decades of international experience in finance and business development. Previously, Mr Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. And since January 2010, he has been a member of the board and chair of the audit committee for Tekmira Pharmaceuticals, a publicly held biopharmaceutical company.
You may also be interested in...
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.